Impact of measurable residual disease in combination with CD19 on postremission therapy choices for adult t(8;21) acute myeloid leukemia in first complete remission

Impact of measurable residual disease in combination with CD19 on postremission therapy choices for adult t(8;21) acute myeloid leukemia in first complete remission

Abstract Background The post‐remission therapy (PRT) choices for adult t(8;21) acute myeloid leukemia (AML) in first complete remission (CR1) need to be further explored. Aims We aimed to investigate the impact of measurable residual disease (MRD) combined with CD19 on PRT choices for adult t(8;21)...

Full description

Bibliographic Details
Main Authors: Xi Jia, Naying Liao, Sijian Yu, Huan Li, Hui Liu, Haiyan Zhang, Jun Xu, Yunqian Yao, Han He, Guopan Yu, Qifa Liu, Yu Zhang, Pengcheng Shi
Format: Article
Language:English
Published: Wiley 2024-02-01
Series:Cancer Medicine
Subjects:
allogeneic stem cell transplantation
CD19
chemotherapy
MRD
t(8;21) AML
Online Access:https://doi.org/10.1002/cam4.7074

Internet

https://doi.org/10.1002/cam4.7074

Similar Items